P
atients with non-insulin-dependent diabetes mellitus (NIDDM) experience disproportionate morbidity and mortality from ischemic heart disease. 1 The observation that NIDDM specifically increases the incidence of congestive heart failure 2 and death 3 after an index myocardial infarction implies that this adverse risk may reflect a primary impairment in myocardial ischemic tolerance. Considerable evidence now suggests that the myocardium adapts to ischemia in part by increasing its uptake and energetic metabolism of glucose via recruitment of specific elements of the intrinsic myocardial insulin-response system. 4, 5 This raises the question of whether the development of NIDDM in patients with ischemic heart disease is associated with impaired expression and/or function of this system.
Most previous attempts to address this question have used the technique of [ 18 F]fluorodeoxyglucose PET to indirectly estimate the myocardial glucose uptake response to systemic insulin administration. These studies have yielded mixed results. 6 -9 More important, systemic insulin administration stimulates myocardial glucose uptake mainly indirectly by suppressing lipolysis in adipocytes and lowering the plasma fatty acid concentration, which removes fatty acid inhibition of heart glucose uptake and oxidation. 10 This does not allow direct assessment of the interaction of insulin with the insulin-response system of the heart itself. To circumvent these limitations, in the present study we combined local intracoronary insulin infusion with direct measurement of arterial-coronary sinus glucose balance to compare the intrinsic myocardial responsiveness to insulin in ischemic heart disease patients with and without NIDDM.
Methods Subjects
Twenty-six male subjects were enrolled from the population referred for evaluation of chest pain. Subject characteristics are listed in Table 1 . Thirteen had NIDDM (duration, 6Ϯ4 years; range, 1 to 18 years), and 13 were nondiabetic control subjects. Subjects were excluded if they had reduced left ventricular ejection fraction (Ͻ45%), previous myocardial infarction, or chest pain within 24 hours preceding study. All subjects were taking ␤-adrenergic blockers and aspirin. Hypoglycemic medications (glyburide in 10 subjects and insulin in 3) were withdrawn Ն48 hours before study.
Experimental Protocol
The study protocol was approved by the Human Subjects Committee of the VA Connecticut Healthcare System, and all subjects gave written informed consent. After a 12-to 16-hour fast, sampling catheters were placed in a femoral artery and the proximal coronary sinus as previously described, 11 and subjects received 5000 U IV heparin sodium to prevent vascular thrombosis. In 12 subjects (6 with NIDDM and 6 control subjects), a Baim model thermodilution catheter (Electrocatheter Co) was placed in the coronary sinus to allow measurement of blood flow. 11 Twenty minutes after heparin administration, quadruplicate paired samples of arterial and coronary venous blood were obtained at 3-minute intervals for measurement of glucose, lactate, free fatty acid (FFA), insulin, and hemoglobin concentrations; coronary sinus blood flow was measured in triplicate.
Next, a catheter (JL-4, Cordis Inc) was advanced into the left main coronary artery. Through this catheter, a 40-mU · mL solution of human insulin (Humulin, Eli Lilly) in saline was infused continuously into the left coronary at 0.25 mL · min (10 mU · min) for 70 minutes. This rate was chosen to raise coronary plasma insulin concentration from the fasting into the upper physiological range without significantly increasing systemic insulin concentration. Because blood flow in the left coronary artery averages Ͼ50 mL · min, 11 experimental infusion at 0.25 mL · min would not be expected to artifactually change coronary flow or substrate concentrations. Measurements were repeated during the final 10 minutes of infusion. Coronary angiography and left ventriculography were then performed.
Analytical Methods
Plasma glucose and lactate concentrations were measured with an automated glucose oxidase/lactate oxidase analyzer (Statplus 2000, YSI Inc) calibrated to external standards and with a betweenmeasures variance of 1.0%. Plasma FFA concentration was measured with a microfluorometric modification of the Dole procedure. 12 Plasma insulin concentration was measured with a doubleantibody radioimmunoassay kit (New England Nuclear Corp).
Calculations
Arterial-coronary sinus balance (mol · L) for glucose, lactate, and FFA was calculated by subtracting their coronary sinus concentration from their arterial plasma concentration. These differences were then divided by arterial concentration and multiplied by 100 to give a percent extraction from arterial plasma for each substrate. For subjects in whom coronary sinus flow was measured, myocardial net uptake (mol · min) of glucose, lactate, and FFA was calculated by multiplying the arterial-coronary sinus balance by coronary sinus plasma flow (blood flowϫ[1Ϫhematocrit]). Myocardial oxygen consumption was determined by the Fick principle after calculation of arterial and coronary venous blood oxygen content (mL · L). 11 
Data Analysis
Results from quadruplicate sets of plasma samples were averaged to yield 1 value for each measured variable under basal and insulininfused conditions for each subject. All data are expressed as meanϮSD. Within each group, comparisons between the 2 sampling times were made by paired t tests. Comparisons between the 2 groups at each sampling time were made by 2-tailed unpaired t tests. A sample size of 11 patients per group provides 80% power to detect a 15% difference in glucose AV balance between NIDDM and control subjects, assuming 11 an SD of 16 and 35 mol · L for measurement of glucose and lactate AV balances, respectively, and using a 5% two-tailed significance level.
Results

Hemodynamic and Angiographic Data
Basal systolic and diastolic blood pressures, heart rate, and rate-pressure product (systolic blood pressure times heart rate) were similar in control subjects (125ϩ11 mm Hg, 70ϩ6 mm Hg, 61ϩ7 minutes
Ϫ1
, and 7628ϩ79 mm Hg · min) and NIDDM patients (131ϩ13 mm Hg, 75ϩ9 mm Hg, 66ϩ8 minutes
, and 8644ϩ109 mm Hg · min; all PϭNS) and were not significantly affected by intracoronary insulin infusion in either group (control: 131ϩ14 mm Hg, 73ϩ9 mm Hg, 60ϩ7 minutes
, and 7859ϩ99 mm Hg · min; NIDDM: 133ϩ15 mm Hg, 73ϩ11 mm Hg, 68ϩ9 minutes
, and 9035ϩ138 mm Hg · min). All subjects were found to have significant (Ͼ50% luminal narrowing) atherosclerosis affecting Ն1 major coronary artery (average number of arteries involved: nondiabetic, 2.2Ϯ0.6; NIDDM, 2.0Ϯ0.5), but the left anterior descending and circumflex branches of the left main coronary were observed to be patent and to perfuse the major portion of the left ventricular muscle in all.
Plasma Substrate and Insulin Concentrations
In the basal state, NIDDM subjects had higher arterial plasma concentrations of glucose (8.9Ϯ1.1 versus 5.3Ϯ0.7 mol · mL, PϽ0.01) and insulin (26Ϯ5 versus 13Ϯ4 U · mL, PϽ0.05) and higher hemoglobin A Ic levels (8.0Ϯ1.2 versus 5.3Ϯ1.0%, PϽ0.05) than nondiabetic control subjects (Table  1) . Plasma lactate levels were marginally higher in NIDDM patients (0.8Ϯ0.3 versus 0.6Ϯ0.2 mol · mL, Pϭ0.10), whereas FFA levels were uniformly high in both groups (1.2Ϯ0.3 versus 1.3Ϯ0.3 mol · mL, PϭNS), consistent with the fasting state and heparin administration. Intracoronary insulin infusion succeeded in raising the coronary venous plasma insulin concentration to slightly above the physiological range in both groups (142Ϯ14 versus 156Ϯ20 U · mL for control subjects versus NIDDM patients, PϭNS) without substantially increasing the systemic arterial insulin level ( Figure 1 ). Arterial plasma glucose, lactate, and FFA concentrations were not affected by insulin infusion in either group (Table 2) , confirming the lack of any systemic metabolic insulin effect during intracoronary infusion.
Coronary Sinus Blood Flow and Myocardial Oxygen Consumption
Intracoronary insulin infusion increased coronary sinus blood flow in each of 6 nondiabetic subjects by an average of Ϸ20% 
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(from 53Ϯ7 to 62Ϯ9 mL · min, PϽ0.001). This was accompanied by a corresponding increase in coronary venous oxyhemoglobin saturation (from 31Ϯ5% to 39Ϯ5%, PϽ0.01) so that calculated myocardial oxygen consumption did not change (6.8Ϯ1.3 to 7.0Ϯ1.6 mL · min, PϭNS). In contrast, 0 of the 6 NIDDM subjects demonstrated a significant change in either coronary sinus flow (55Ϯ10 to 56Ϯ11 mL · min, PϭNS) or myocardial oxygen consumption (6.6Ϯ1.8 to 6.2Ϯ1.9 mL · min, PϭNS) during insulin infusion (Figure 2 ).
Arterial-Coronary Sinus Balance, Percent Extraction, and Net Uptake
Arterial-coronary sinus balance and fractional myocardial extraction of glucose, lactate, and FFA for each group are shown in Figure 3 . For glucose, in the fasting state, its fractional extraction from arterial plasma in nondiabetics was twice that of NIDDM patients (2.1Ϯ0.5% versus 1.0Ϯ0.5%, PϽ0.01). However, because NIDDM patients had higher arterial plasma glucose concentrations, the net arterialcoronary sinus balances of the 2 groups were equivalent (109Ϯ16 versus 99Ϯ16 mol · L, PϭNS). Intracoronary insulin infusion increased glucose extraction and arterialcoronary sinus balance Ϸ2.5-fold in control subjects (to 5.4Ϯ0.7% and 294Ϯ36 mol · L, both PϽ0.001 versus basal) and Ϸ3.5-fold in NIDDM patients (to 3.7Ϯ0.6% and 337Ϯ48 mol · L, both PϽ0.001 versus basal) Basal lactate extraction was marginally higher in nondiabetic than in NIDDM patients (33Ϯ7% versus 25Ϯ7%, Pϭ0.02), but because NIDDM patients had slightly higher arterial lactate concentrations, arterial-coronary sinus balances for the 2 groups were equivalent (208Ϯ32 versus 213Ϯ31 mol · L, PϭNS). During intracoronary insulin infusion, all subjects demonstrated an increase in fractional extraction and arterial-coronary sinus balance for lactate, with no significant difference in the response of control subjects (to 46Ϯ7% and 278Ϯ39 mol · L) and NIDDM (to 35Ϯ5% and 283Ϯ34 mol · L) patients.
Basal extraction and arterial-coronary sinus balance of FFA were high, consistent with the high arterial FFA levels of these subjects who were fasting and had received heparin, but they were not different between groups. Intracoronary insulin infusion had no effect on fractional extraction or arterialcoronary sinus balance of FFA in either NIDDM patients or control subjects. Table 3 lists the corresponding values for net myocardial substrate uptake for the 6 subjects in each group in whom myocardial blood flow was measured. Consistent with the arterial-coronary sinus balance data, intracoronary insulin infusion increased net myocardial glucose uptake Ϸ3-fold and lactate uptake Ϸ40% in both control subjects and NIDDM patients, and there were no differences in the magnitude of insulin-stimulated glucose or lactate uptake between the groups (PϾ0.20 for all comparisons).
Discussion
In this study, we used direct techniques to measure the response of the arterial-coronary sinus glucose balance to an increment in local intracoronary insulin concentration. Because this balance is quantitatively determined by the operation of a number of insulin-responsive metabolic processes within the heart, we reasoned that this measurement should provide an assay of the functional integrity of this integrated insulin-response system. We observed that raising local coronary insulin concentration from a fasting to a slightly supraphysiological level increased myocardial glucose uptake equivalently in ischemic heart disease patients with and without NIDDM. This suggests that in such patients, the development of NIDDM does not impair the intrinsic insulinresponse capacity of the heart with respect to glucose consumption.
In the fasting state, our NIDDM patients differed from nondiabetic control subjects in exhibiting hyperglycemia and hyperinsulinemia. These traits are known to indicate resistance to the insulin stimulation of glucose uptake by skeletal muscles, the major target tissue for insulin action. 13 Correspondingly, we observed that fasting heart glucose uptake in NIDDM patients was merely equivalent to that of control subjects despite higher fasting glucose and insulin levels. This suggests that both skeletal and cardiac muscles of NIDDM patients are insulin resistant during fasting relative to those of nondiabetic control subjects. Because transmem- brane transport is generally considered to be rate limiting for muscle glucose consumption during fasting, this further implies a fasting impairment in myocardial glucose transport in NIDDM, as has been described for skeletal muscles. 14 The observation that NIDDM subjects and control subjects nevertheless exhibited a quantitatively similar glucose-uptake response to local insulin administration can perhaps be explained in the context of our present understanding of muscle glucose metabolism. Insulin stimulates muscle glucose uptake primarily by effecting translocation of the GLUT4 transporter from an intracellular compartment to the sarcolemma. 15 Although a variety of defects in intracellular glucose metabolism have been described in individuals or families with NIDDM, 13 studies measuring the rate of muscle glucose-6-phosphate accumulation during insulin stimulation have established that the insulin resistance of NIDDM primarily involves an impairment in muscle glucose transport/ phosphorylation. 16 After its transmembrane transport, the major metabolic fate of glucose imported into both human heart 17 and skeletal muscles 18 is storage in the form of glycogen. Insulin stimulation of glycogen synthesis in skeletal muscle is also specifically impaired in NIDDM, 19 and this impairment accounts quantitatively for almost all the reduction in net glucose consumption in NIDDM muscles. 20 Because even healthy prediabetic offspring of NIDDM patients exhibit impaired insulin stimulation of skeletal muscle glucose transport 21 and glycogen synthesis, 22 it has been suggested that the disease involves genetically transmitted defects in muscle glucose transporter and glycogen synthase expression. 13 How can this be reconciled with the present finding that in NIDDM patients exhibiting insulin resistance of peripheral tissues, cardiac muscle nevertheless appears to remain as insulin responsive as in nondiabetic subjects? The answer may lie in the markedly different contractile work histories of cardiac versus skeletal muscles. In limb muscles of insulin-resistant subjects, contractile exercise increases the capacity for both glucose transport 23 and glycogen synthesis. 24 In contrast, reducing cardiac workload downregulates myocardial GLUT4 expression 25 and produces marked resistance to stimulation of glycogen synthesis by even supraphysiological doses of insulin. 26 Thus, the preserved insulin response of the NIDDM heart, relative to other tissues of the body, may reflect the protective effect of repetitive, highfrequency contractile work on glucose transporter and glycogen synthase expression and function.
Obtaining a maximum energy yield from imported glucose requires glycolytic conversion to pyruvate and subsequent mitochondrial oxidation. Although we did not directly measure myocardial glucose oxidation in this study, the finding that local hyperinsulinemia increased net myocardial uptake of lactate and glucose would be consistent with stimulation of glucose carbon flux through pyruvate dehydrogenase, the rate-limiting step for lactate and pyruvate entry into the citric acid cycle. Augmenting myocardial pyruvate dehydrogenase flux has been demonstrated to improve the functional recovery from ischemia in the isolated heart. 27 The observation that insulin widened the arterial-coronary sinus lactate balance by an equivalent amount in control subjects and NIDDM patients suggests that the capacity for this important response may also be preserved in the NIDDM heart. Although hyperinsulinemia in the midphysiological range (50 to 60 U/mL) appears to be without effect on coronary blood flow in humans, 28 we previously observed that raising the systemic insulin level to Ϸ200 U/mL increases it by Ϸ20%. 11 The similar response to local hyperinsulinemia in the present study, unaccompanied by any change in myocardial oxygen demand or consumption, suggests a direct, local insulin action on coronary arterial tone. It is well established that insulin exerts an endothelium-dependent, nitric oxidemediated vasodilatory action in skeletal muscle. 29 In that tissue, the magnitude of the effect tracks the magnitude of the effect of insulin on tissue glucose uptake and thus is progressively blunted by the development of insulin resistance and NIDDM. 30 Although fewer data are available concerning the heart, a similar loss of vasodilator response to intracoronary insulin infusion has been reported to accompany the development of whole-body insulin resistance in canines. 31 On the basis of observations in skeletal muscles, a number of explanations could be considered for the impaired blood flow response observed in NIDDM patients, including a primary defect in coronary endothelial function, more extensive atherosclerosis, or simply their prevailing hyperglycemia. 32 The present observations do not allow these to be distinguished and furthermore involve only a small number of subjects. Nevertheless, they suggest that at least in the heart, the insulin responsiveness of vascular tissue and muscle may be mediated independently.
The study has several limitations. NIDDM patients were studied at plasma glucose concentrations Ϸ70% higher than nondiabetic control subjects. This might be predicted to increase the absolute magnitude of their heart glucose uptake by mass action, even in the face of diminished intrinsic insulin responsiveness. Nevertheless, studies of the wholebody response to insulin in NIDDM demonstrate that even hyperglycemic insulin infusion produces less than one half the fractional increase in whole-body glucose uptake produced by euglycemic infusion in nondiabetic subjects. 33 In the case of tissues of the whole body, this difference is attributable to both a rightward shift in the insulin doseresponse curve and decreased maximal insulin response. 33 The present results demonstrating proportionally equal insulin stimulation of myocardial glucose uptake in control subjects and NIDDM patients suggest that these changes in insulin sensitivity and response capacity are not demonstrable in the heart. Because the study design required fasting and heparin administration, our observations were necessarily made at relatively high circulating FFA levels, which would tend to suppress absolute myocardial glucose uptake. 10 Further studies are needed to determine whether the glucoseuptake response of the NIDDM heart remains equivalent to that of the nondiabetic heart at higher glucose utilization rates. Finally, although we did not directly measure wholebody insulin sensitivity in these subjects, our previous observations 11 suggest that even in the absence of NIDDM, ischemic heart disease patients exhibit some degree of wholebody insulin resistance relative to age-matched healthy subjects. 28 Because the study did not include control subjects without heart disease, we cannot distinguish whether the myocardial insulin-response characteristics of our NIDDM and nondiabetic groups would have been equivalent to those of healthy subjects or instead simply impaired to an equivalent degree.
In summary, in patients with ischemic heart disease, the development of NIDDM appears to impair the effects of insulin on coronary tone but not on myocardial glucose consumption. Ischemic heart disease patients both with and without NIDDM express equally responsive cardiac metabolic insulin-response systems, which should be equivalent targets for insulin-based metabolic therapy. Net myocardial substrate uptake (mol/min) for glucose, lactate, and FFA in the basal state and during intracoronary insulin infusion. Values are meanϮSD for 6 subjects in each group.
